PatientsVille.com Logo

URINARY TRACT INFECTION and Flagyl

PatientsVille

URINARY TRACT INFECTION Symptoms and Causes

The urinary system is the body's drainage system for removing wastes and extra water. It includes two kidneys, two ureters, a bladder, and a urethra. Urinary tract infections (UTIs) are the second most common type of infection in the body.

You may have a UTI if you notice

  • Pain or burning when you urinate
  • Fever, tiredness, or shakiness
  • An urge to urinate often
  • Pressure in your lower belly
  • Urine that smells bad or looks cloudy or reddish
  • Pain in your back or side below the ribs

People of any age or sex can get UTIs. But about four times as many women get UTIs as men. You're also at higher risk if you have diabetes, need a tube to drain your bladder, or have a spinal cord injury.

If you think you have a UTI it is important to see your doctor. Your doctor can tell if you have a UTI with a urine test. Treatment is with antibiotics.

NIH: National Institute of Diabetes and Digestive and Kidney Diseases

Check out the latest treatments for URINARY TRACT INFECTION

URINARY TRACT INFECTION treatment research studies

Flagyl clinical trials, surveys and public health registries


Find Drug Side Effect reports



Flagyl Side Effects

Diarrhoea (69)
Pyrexia (65)
Paraesthesia (59)
Vomiting (56)
Nausea (53)
Dizziness (51)
Hypoaesthesia (46)
Rash (44)
Pain (44)
Neuropathy Peripheral (43)
Abdominal Pain (43)
Confusional State (41)
Pruritus (37)
Dyspnoea (37)
Weight Decreased (36)
Urticaria (36)
Chills (34)
Thrombocytopenia (32)
Dysgeusia (31)
Headache (29)
Hypersensitivity (29)
Renal Failure Acute (27)
Anxiety (27)
Erythema (26)
Convulsion (26)
Oedema Peripheral (23)
Insomnia (22)
Neutropenia (22)
Asthenia (22)
Cholestasis (22)
Malaise (21)
Fatigue (21)
Anaemia (20)
Burning Sensation (19)
Fall (18)
Gait Disturbance (18)
Arthralgia (18)
Alanine Aminotransferase Increased (17)
Clostridium Difficile Colitis (17)
Abdominal Discomfort (17)
Depression (17)
Toxic Skin Eruption (17)
Muscle Spasms (17)
Hepatitis (16)
Hypotension (16)
Pancreatitis Acute (16)
Pain In Extremity (16)
Tremor (16)
Pancreatitis (15)
Polyneuropathy (15)

➢ More


Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)
Zoloft(6792)
Zyrtec(1669)

Recent Reviews

Hi few days ago i went to my gp with urine burning pain leftside of belly bit blood in urine and now i have small swelling to my belly near belly button it feels sore and hurts when i touch it can anyone out there plz help me

Hi, I have had A UTI for feels like month now I was put on Cipro did not work now I am on Baxtrum, almost done with it but I am not getting better I feel worse now with aching in my left side. Whta is going on, I just feel not myself either. should I

I am currenty on Flagyl for a pelvic infection in combination with vibramyacin. This morning I took the vibramyacin and then was planning on taking the Flagyl an hour later, but I spent the this morning vomiting. I called the dr.

I really hate utis how about you?

I took flagyl for 5 days each day feeling worse nausea an inner agitation and yawning for air difficulty breathing.....felt like it was attacking my intestines and the body was reacting and going into flight or fight. Very uncomfortable really unbear

Iam starting antibiodic iam taking cerazett the pill i had sex 5 days ago can i get pregnant

My 2 yr old has just been prescribed this and has to take 5ml 2 times a day he has the suspension at 50mg. this was given for an infection found in water sample. reading the side effect list im worried. has anyone else had this for a child ?

My son was treated with flagyl and vancomycin for cdiff. Today after 2 weeks off vanco he has mucus in his stool. Does he still have cdiff? What should we do

The exact same thing happened to me after I was prescribed high dose flagyl for 5 days for suspected diverticulitis (painful bloating, frothy yellow diarrhea, excessive foul gas, etc.) my doc also put me on a Clear Liquid Diet for 3 days before I h

In Oct. 2010 I had a penile implant surgery. One month to the day it was removed because of infection. I have had 3 1/2 month that I wouldn't wish on anyone. It's now 4 months later and the Dr. tells me he wouldn't a

48 years of age. I was diagnosed with urinary tract infection. Had one dose of monuril 3 gr. After 7 hours developed skin rash on the back, arms and neck, generally swelling of the face, specially below the eyes, Had oral antihistamine and went to

I have an ear infection where my ear canal is covered in blisters and blood/fluid coming out, also mu ear is completely blocked. I am on antibiotics and drops but a friend mentioned that they took oflocet 200mg when had a similar problem, but I hav

I am sorry you are in pain. But did you not just say you have Pneumonia!? I think that life threatening infection is worse than the diarrhea dont you?

I have been taking ciprofloxacina for an stomacal infection. It has worked well, I feel much better but I have experienced dizziness (a lot of dizziness).

<b>Describe Your Pinaclor Experience Here:</b> was put on pinaclor for surgical wound infection at end of course got lumps on head

<span style='color: #808080;'><strong>I have an 11 yr old yorkie that has been on Clavamox 375 mgm for several cycles since end of April. He is also on FlortiFLora to avoid colon distress. His mouth infection has not g

<strong></strong><span style='color: #808080;'>id like to see more photos on the corneal leucoma patients inorder to appretiate the existence of such an eye infection...

<strong>My son who is 6 years old, had finished a whole round of a different antibiotic for sinus infection- he is up to 25 days of coughing. 4 days ago he was prescribed Biaxin. He has been vomiting -both ends - diarrhea- with severe rash all

'Foreign proteins that gain access to the body through cuts and scrapes, through the digestive or circulatory systems, or through the urinary and reproductive systems are called ____.' Answer a) immunoglobulins

URINARY TRACT INFECTION Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Recruiting Azithromycin Based Therapy for Induction of Remission in Active Pediatric Crohn's Disease
Condition: Crohn's Disease
Interventions: Drug: Azithromycin + Metronidazole;   Drug: Metronidazole
Outcome Measures: Response rate at 8 weeks defined as a drop in PCDAI (Pediatric Crohn's Disease Activity Index ) of at least 12.5 points (or remission without steroids, intention to treat principle);   Normalization of CRP ( CRP ≤0.5 mg/dL).;   Fecal calprotectin at 8 weeks .
2 Not yet recruiting Study to Determine the Equivalence of Three Products Containing Metronidazole Benzoate.
Condition: Bacterial Infections
Interventions: Drug: Metronidazole benzoate;   Drug: Flagyl 125 mg/5 ml oral suspension;   Drug: Flagyl 400 mg Tablets
Outcome Measures: Plasma concentration time profiles under the curve (AUC);   Maximum concentration (Cmax);   Time to maximum concentration (Tmax);   Elimination rate constant (Kel);   Terminal half life (t1/2);   Number of participants with Adverse Events
3 Recruiting Comparison Between Oral Clindamycin Vs Metronidazole for the Treatment of Abnormal Vaginal Flora in High Risk Pregnancies
Conditions: Abnormal Vaginal Flora;   Clindamycin Vs Metronidazole;   High Risk Pregnancies for Preterm Labor
Interventions: Drug: Clindamycin;   Drug: Metronidazole
Outcome Measures: To compare the efficacy between oral Clindamycin Vs Metronidazole in the eradication of abnormal vaginal flora;   The prevalence of adverse effects;   The prevalence of late abortions and preterm deliveries;   Assessing the correlation between Nugent score , physical examination and Ph indicators
4 Recruiting BASIC (Boric Acid, Alternate Solution for Intravaginal Colonization) Study
Condition: Bacterial Vaginosis
Interventions: Drug: Gelatin;   Drug: Boric acid;   Drug: Metronidazole
Outcome Measures: Effectiveness of treatment of intravaginal boric acid and metronidazole at 1 week and 30 days post-treatment will be measured as absence of symptoms or negative vaginal swab (Nugent score less than 7) if symptoms are present for BV.;   If during the 10 days of treatment of intravaginal boric acid and metronidazole the patient discontinues the treatment because of side effects or complained of intolerable side effects this will be considered a treatment failure for safety.
5 Recruiting Role of N-Acetylcysteine in Treatment of Bacterial Vaginosis
Condition: Bacterial Vaginosis
Interventions: Drug: N-Acetyl cysteine;   Drug: Metronidazole + N-Acetyl cysteine;   Drug: metronidazole
Outcome Measures: recovery of BV;   prevention of recurrence
6 Unknown  Increased Re-eradication Rate of Helicobacter Pylori by Adding N-acetylcystein or Metronidazole to the Triple Therapy
Condition: Bacterial Infection Due to Helicobacter Pylori (H. Pylori)
Interventions: Drug: 10RAC+acetylcystein;   Drug: 10RAC+metronidazole
Outcome Measures: Re-eradication rate;   Influence of Participant's CYP2C19 genotype on re-eradication rate
7 Unknown  Inflammation and Treatment of Bacterial Vaginosis Near Term
Condition: Bacterial Vaginosis
Interventions: Drug: Metronidazole;   Drug: Placebo
Outcome Measure: Levels of Interleukins 1 and 6 as well as Tumor Necrosis Factor Alpha
8 Recruiting Impact of Oral Antibiotic Treatment on C. Difficile
Conditions: C. Difficile;   Diarrhea;   Enterocolitis
Interventions: Drug: Fidaxomicin;   Drug: Metronidazole;   Drug: Vancomycin
Outcome Measures: Change in variation of the profile of C. difficile isolated from specific body sites of a patient with microbiology-proven CDAD;   Change in variation in the profile of C. difficile isolated from targeted surfaces in a hospital;   Extent and quantity of C. difficile shedding, colonization and environmental contamination in patients who received oral fidaxomicin vs. oral metronidazole or vancomycin;   Duration of diarrhea that were positive for CDAD
9 Unknown  Moxifloxacin Plus Metronidazole Versus Piperacillin/Tazobactam for the Treatment of Patients With Intra-abdominal Abscesses
Condition: Abscess, Intra-Abdominal
Intervention: Drug: Moxifloxacin/Metronidazole or Piperacillin/Tazobactam
Outcome Measures: Clinical success / failure rate at the Test-of-Cure visit;   Clinical + Bacteriological response at End-of-Treatment-visit;   Time to discharge from hospital;   Course of disease on the basis of clinical and laboratory parameters;   safety and tolerability of the study medication;   cost effectiveness of treatment regimes
10 Recruiting Comparison of the Eradications Rates of Sequential Therapy Versus Concomitant Therapy
Condition: Helicobacter Pylori Infection
Interventions: Drug: pantoprazole, amoxicillin, clarithromycin, metronidazole;   Drug: pantoprazole, amoxicillin, clarithromycin, metronidzole
Outcome Measure: Comparison of the eradications rates of sequential therapy versus concomitant therapy of treatment of Helicobacter pylori infection in Korea.
11 Recruiting Compare Ceftazidime-Avibactam + Metronidazole Versus Meropenem for Hospitalized Adults With Complicated Intra-Abdominal Infections
Condition: Complicated Intra-Abdominal Infection
Interventions: Drug: CAZ-AVI;   Drug: Metronidazole;   Drug: Meropenem
Outcome Measures: Clinical Cure as Measured by proportion of patients meeting cure criteria in the microbiological modified Intent-To-Treat analysis set.;   The proportion of patients with clinical cure in the microbiologically evaluable and extended microbiologically evaluable analysis set;   The proportion of patients with clinical cure in the microbiological modified intent-to-treat, microbiologically evaluable, and extended microbiologically evaluable analysis sets;   The proportion of patients with clinical cure in the clinically evaluable analysis set.;   The proportion of patients with a favorable per-patient microbiological response in the microbiological modified intent to treat, microbiologically evaluable, and extended microbiologically evaluable analysis sets;   The proportion of favorable per-pathogen microbiological response in the microbiological modified intent to treat, microbiologically evaluable, and extended microbiologically evaluable analysis sets;   The favorable per-pathogen microbiologic response by minimum inhibitory concentration (MIC) categories in the microbiological modified intent to treat, microbiologically evaluable, and extended microbiologically evaluable analysis sets;   Favorable per-patient clinical response & microbiological response for patients infected with ceftazidime-resistant pathogens in microbiological modified intent to treat, microbiologically evaluable & extended microbiologically evaluable analysis sets;   Proportion of patients with favorable per-pathogen microbiological response for patients infected with ceftazidime-resistant pathogens in microbiological modified ITT, microbiologically evaluable and extended microbiologically evaluable analysis sets;   The time to first defervescence in the clinically evaluable, microbiologically evaluable, and extended microbiologically evaluable analysis sets for patients who have fever at study entry;   The safety and tolerability by incidence and severity of adverse events and serious adverse events, vital signs, clinical laboratory tests, ECGs and physical exams.;   Pharmacokinetics: maximum concentration (Cmax), minimum concentration, area under the plasma concentration time curve at steady state, and terminal half-life
12 Recruiting Compare Ceftazidime-Avibactam + Metronidazole vs Meropenem for Hospitalized Adults With Complicated Intra-Abd Infections
Condition: Complicated Intra-abdominal Infection
Interventions: Drug: Ceftazidime-avibactam;   Drug: metronidazole;   Drug: Meropenem
Outcome Measures: The proportion of patients with clinical cure in the clinically evaluable analysis set;   The proportion of patients with clinical cure in the microbiologically evaluable, extended microbiologically evaluable and microbiological modified intent-to-treat analysis sets;   The proportion of patients with a favorable per-patient microbiological response in the microbiological modified intent to treat, microbiologically evaluable and extended microbiologically evaluable analysis sets;   The proportion of favorable per-pathogen microbiological response in the microbiological modified intent to treat, microbiologically evaluable and extended microbiologically evaluable analysis sets;   The favorable per-pathogen microbiologic response by minimum inhibitory concentration categories in the microbiological modified intent to treat, microbiologically evaluable and extended microbiologically evaluable analysis sets;   Favorable clinical response and favorable per-patient microbiological response for patients infected with ceftazidime-resistant pathogens in the microbiological modified intent to treat and (extended) microbiologically evaluable analysis sets;   The proportion of patients with a favorable per-pathogen microbiological response for patients infected with ceftazidime-resistant pathogens in the microbiological modified intent to treat and (extended) microbiologically evaluable analysis sets;   The time to first defervescence in the clinically evaluable, microbiologically evaluable and extended microbiologically evaluable analysis sets for patients who have fever at study entry;   Safety and tolerability by incidence and severity of adverse events and serious adverse events, exposure, mortality, reasons for discontinuations of study therapy, vital signs, laboratory tests, electrocardiogram parameters and physical exams
13 Unknown  Effects of the Variation in the Time of Systemic Administration of Metronidazole and Amoxicillin Associated to the Non-surgical Therapy of Chronic Periodontitis.
Conditions: Chronic Periodontitis;   Clinical and Microbiological Effects
Intervention: Drug: Administration of Metronidazole plus Amoxicillin
Outcome Measures: - Mean change in clinical attachment level (CAL);   - Mean change in probing pocket depths (PD)
14 Recruiting The Use of Erythritol Powder and Metronidazole Gel for the Non-surgical Treatment of Periodontitis
Condition: Periodontal Pocket
Interventions: Drug: metronidazole gel;   Procedure: ultrasonics;   Procedure: erythritol;   Drug: placebo
Outcome Measures: Probing pocket Depth change;   Bleeding on Probing change;   Clinical Attachment level change
15 Not yet recruiting Vaccine Plus Booster Shots in Men With Prostate Cancer Undergoing Treatment With Radical Prostatectomy
Conditions: Prostate Cancer;   Prostatic Neoplasms;   Neoplasms, Prostate
Interventions: Biological: PROSTVAC-V/TRICOM;   Biological: PROSTVAC-F/TRICOM
Outcome Measures: Changes from baseline to after surgery of CD4 and CD8 cell infiltrates;   Change in peripheral PSA-specific T cells;   Any intraprostatic Treg cell infiltration with CD4+FOX-P3 staining;   Any PSA changes secondary to vaccination;   Any MRI changes secondary to vaccination
16 Unknown  The Impact of Obesity on Nonsurgical Periodontal Therapy
Conditions: Periodontitis;   Periodontal Diseases;   Obesity
Interventions: Drug: Metronidazole;   Drug: Placebo;   Procedure: Scaling and root planning
Outcome Measures: Probing depth;   Attachment level
17 Recruiting Concomitant Therapy of H. Pylori
Condition: Gastritis, Gastric Ulcer, and Duodenal Ulcer
Intervention: Drug: amoxicillin, clarithromycin, metronidazole, rabeprazole
Outcome Measure: Evaluation of the efficacy of concomitant therapy for eradication of Helicobacter pylori
18 Recruiting Antibiotic Safety (SCAMP)
Condition: Complicated Intra Abdominal Infections
Interventions: Drug: ampicillin and metronidazole and gentamicin;   Drug: ampicillin and gentamicin and clindamycin;   Drug: gentamicin and Piperacillin- tazobactam;   Drug: standard of care antibiotics and metronidazole
Outcome Measures: Death;   Number of participants with therapeutic success at Day 30 and Day 90
19 Recruiting Enzalutamide in Combination With PSA-TRICOM in Patients With Non-Metastatic Castration Sensitive Prostate Cancer
Condition: Prostate Cancer
Interventions: Biological: PROSTVAC-F/TRICOM;   Biological: PROSTVAC-V/TRICOM;   Drug: Enzalutamide (Xtandi)
Outcome Measures: Decrease in tumor re-growth rate;   Immune response;   Determine impact on PSA
20 Recruiting Efficacy Study of Preconception Treatment of an Asymptomatic Bacterial Infection in an Infertility Population
Conditions: Vaginosis, Bacterial;   Infertility;   Miscarriage
Interventions: Drug: Metronidazole;   Drug: Placebo
Outcome Measures: Biochemical Pregnancy Rate (Positive Pregnancy Test);   Pregnancy Rate (Pregnancy Visible on Ultrasound);   Miscarriage Rate (Loss of a Clinically Recognized Pregnancy);   Infectious Morbidity (i.e. Chorioamnionitis, Neonatal Sepsis)